Jia Zhe, Zhang Ke, Jiang Li, Huang Ronghai, He Rong, Wang Zhenjun
Department of General Surgery, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P.R. China.
Department of General Surgery, Beijing Di Tan Hospital, Capital Medical University, Beijing, P.R. China.
Minim Invasive Ther Allied Technol. 2020 Jun;29(3):177-184. doi: 10.1080/13645706.2019.1609990. Epub 2019 May 22.
This study aimed to evaluate the safety and effectiveness of simultaneous radiofrequency ablation (RFA) combined with laparoscopic splenectomy (Lap-Sp) for patients with hepatocellular carcinoma (HCC) complicated with cirrhosis and hypersplenism. Between January 2013 and June 2014, 42 patients with primary HCC complicated with cirrhosis and hypersplenism who underwent simultaneous RFA combined with Lap-Sp were enrolled at the Department of General Surgery, Beijing Di Tan Hospital. The median number of tumors ablated using RFA was one (range 1-3), and the median sum of the maximum diameter of tumors was 2.5 cm (range 1.2-5.4 cm). The related indicators before and after surgery, complications, and long-term effects were retrospectively analyzed. The median operative time for 42 patients undergoing simultaneous RFA combined with Lap-Sp was 4.5 h (range 2.5-8.5 h), and the median blood loss was 120 mL (range 5-2200 mL). The incidence of moderate-to-severe postoperative complications and the perioperative mortality after surgery were 31.0 and 0%, respectively. The disease-free survival rate for one, three, and five years was 73.8, 19.7, and 16.4%, respectively. The overall survival rate was 90.5, 73.3, and 60.4%, respectively. Simultaneous RFA combined with Lap-Sp was safe and effective for patients with HCC complicated with cirrhosis and hypersplenism.
本研究旨在评估射频消融(RFA)联合腹腔镜脾切除术(Lap-Sp)治疗肝细胞癌(HCC)合并肝硬化及脾功能亢进患者的安全性和有效性。2013年1月至2014年6月,北京地坛医院普通外科收治了42例原发性HCC合并肝硬化及脾功能亢进且接受RFA联合Lap-Sp手术的患者。RFA消融肿瘤的中位数为1个(范围1 - 3个),肿瘤最大直径之和的中位数为2.5 cm(范围1.2 - 5.4 cm)。对手术前后的相关指标、并发症及远期疗效进行回顾性分析。42例行RFA联合Lap-Sp手术患者的中位手术时间为4.5小时(范围2.5 - 8.5小时),中位失血量为120 mL(范围5 - 2200 mL)。术后中重度并发症发生率及围手术期死亡率分别为31.0%和0%。1年、3年和5年无病生存率分别为73.8%、19.7%和16.4%。总生存率分别为90.5%、73.3%和6缉0.4%。RFA联合Lap-Sp治疗HCC合并肝硬化及脾功能亢进患者安全有效。